BioPharmSignal logoBioPharmSignal

Biotech News

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma (LYEL)Lyell ImmunopharmaCompany update

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Translational data support biological basis for durable responses, including enhanced memory potential

Related news

LYELLyell Immunopharma2026-06-04 20:05 EST

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

CGEMCullinan Therapeutics, Inc.2026-06-06 09:15 EST

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

IMTXImmatics2026-06-01 12:00 EST

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

View all latest news

Lyell Immunopharma

Next-Generation CAR-T Therapies Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors. Ronde-cel Ronde-cel is an autologous CAR-T product with an OR-gated design targeting either CD19 or CD20. Its manufacturing process enriches...

Recent company news

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

LYELLyell Immunopharma2026-06-12 16:45 EST

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

LYELLyell Immunopharma2026-06-08 10:00 EST

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

LYELLyell Immunopharma2026-06-04 20:05 EST

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Stock data

Close
14.21 USD
Market cap
347.44M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States